Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.

Ma J, Fu J, Guo N, Liu Z

Alternative therapies in health and medicine1 Aug 2024Cited by 3 (Europe PMC)

PMID38294744PepBankPUB-38294744

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanRandomized controlled trialSafety outcome
In patients with early diabetic nephropathy and type 2 diabetes, no adverse events occurred and no deaths were reported in any of the three groups.
In plain wordsIn people with early diabetic kidney disease, no side effects and no deaths were reported in any of the three groups.
Peptide
Liraglutide
Outcome
No significant changeAdverse events and deaths
Study
n = 120
Comparator
Conventional therapy and dapagliflozin groups
Outcome group
Adverse events · Whole body
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
No adverse events occurred during the treatment period in any of the three groups, and there were no reported deaths.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474416
02HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered fasting plasma glucose more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered fasting blood sugar more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Post-treatment analysis revealed that in terms of blood glucose, FPG, 2hPG, and HbA1c decreased more significantly in the liraglutide and dagliflozin groups compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474401
03HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered 2-hour plasma glucose more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered blood sugar after a glucose load more than usual treatment alone.
Peptide
Liraglutide
Outcome
Decrease2-hour plasma glucose
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Post-treatment analysis revealed that in terms of blood glucose, FPG, 2hPG, and HbA1c decreased more significantly in the liraglutide and dagliflozin groups compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474402
04HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered HbA1c more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered HbA1c more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Post-treatment analysis revealed that in terms of blood glucose, FPG, 2hPG, and HbA1c decreased more significantly in the liraglutide and dagliflozin groups compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474403
05HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered total cholesterol more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered total cholesterol more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseTotal cholesterol
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Lipids · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Regarding lipids, TC, TG, and LDL-C decreased more significantly in the liraglutide and dagliflozin groups compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474404
06HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered triglycerides more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered triglycerides more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Lipids · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Regarding lipids, TC, TG, and LDL-C decreased more significantly in the liraglutide and dagliflozin groups compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474405
07HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered LDL-C more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered LDL cholesterol more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseLDL-C
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Lipids · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Regarding lipids, TC, TG, and LDL-C decreased more significantly in the liraglutide and dagliflozin groups compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474406
08HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered HOMA-IR more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered a measure of insulin resistance more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseHOMA-IR
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
For pancreatic islet function, HOMA-IR and HOMA-β decreased more significantly compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474407
09HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered HOMA-β more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered a measure of beta-cell function more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseHOMA-β
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
For pancreatic islet function, HOMA-IR and HOMA-β decreased more significantly compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474408
10HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered weight more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered weight more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Weight and BMI decreased more significantly in the liraglutide and dagliflozin groups compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474409
11HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, adding liraglutide lowered BMI more than conventional therapy alone.
In plain wordsIn people with early diabetic kidney disease, adding liraglutide lowered BMI more than usual treatment alone.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Weight and BMI decreased more significantly in the liraglutide and dagliflozin groups compared to the conventional group (all P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474410
12HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, hepatic function did not differ significantly among the three groups after treatment.
In plain wordsIn people with early diabetic kidney disease, liver function did not differ between the groups after treatment.
Peptide
Liraglutide
Outcome
No significant changeHepatic function after treatment
Study
n = 80
Comparator
Conventional hypoglycaemic therapy alone
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
However, there were no significant differences in hepatic function among the three groups after treatment
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474411
13HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, fasting plasma glucose differed significantly between liraglutide and dapagliflozin groups.
In plain wordsIn people with early diabetic kidney disease, fasting blood sugar differed between the liraglutide group and the dapagliflozin group.
Peptide
Liraglutide
Outcome
Direction not reportedFasting plasma glucose, liraglutide versus dapagliflozin
Study
n = 80
Comparator
Dapagliflozin added to conventional therapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Post-treatment comparisons between the liraglutide and dagliflozin groups revealed significant differences in FPG, HbA1c, body weight, and BMI (all P < .05)
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474412
14HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, HbA1c differed significantly between liraglutide and dapagliflozin groups.
In plain wordsIn people with early diabetic kidney disease, HbA1c differed between the liraglutide group and the dapagliflozin group.
Peptide
Liraglutide
Outcome
Direction not reportedHbA1c, liraglutide versus dapagliflozin
Study
n = 80
Comparator
Dapagliflozin added to conventional therapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Post-treatment comparisons between the liraglutide and dagliflozin groups revealed significant differences in FPG, HbA1c, body weight, and BMI (all P < .05)
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474413
15HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, body weight differed significantly between liraglutide and dapagliflozin groups.
In plain wordsIn people with early diabetic kidney disease, weight differed between the liraglutide group and the dapagliflozin group.
Peptide
Liraglutide
Outcome
Direction not reportedBody weight, liraglutide versus dapagliflozin
Study
n = 80
Comparator
Dapagliflozin added to conventional therapy
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Post-treatment comparisons between the liraglutide and dagliflozin groups revealed significant differences in FPG, HbA1c, body weight, and BMI (all P < .05)
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474414
16HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, BMI differed significantly between liraglutide and dapagliflozin groups.
In plain wordsIn people with early diabetic kidney disease, BMI differed between the liraglutide group and the dapagliflozin group.
Peptide
Liraglutide
Outcome
Direction not reportedBMI, liraglutide versus dapagliflozin
Study
n = 80
Comparator
Dapagliflozin added to conventional therapy
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Post-treatment comparisons between the liraglutide and dagliflozin groups revealed significant differences in FPG, HbA1c, body weight, and BMI (all P < .05)
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected.
Summary · context
According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin group, with 40 cases in each group.
Report a problemFND-3829474415
17HumanRandomized controlled trialEfficacy outcome
In patients with early diabetic nephropathy and type 2 diabetes, the liraglutide group showed significant changes from before to after treatment in glucose, lipid, liver enzyme, insulin and body measures (all P < .05).
In plain wordsIn people with early diabetic kidney disease, the liraglutide group showed measurable changes in blood sugar, blood fats, liver enzymes and body measures after treatment.
Peptide
Liraglutide
Outcome
Direction not reportedWithin-group change from before to after treatment in glucose, lipid, liver enzyme, insulin and body measures
Study
n = 40
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg daily (average) · 12 weeksAs given in this study (human).
Source sentences
Summary
Both the liraglutide and dagliflozin groups exhibited significant changes in FPG, 2hPG, HbA1c, TC, TG, LDL-C, HOMA-IR, FINS, HOMA-β, body weight, BMI, HDL-C, ALT, and AST when compared to the post-treatment period, and these changes were statistically significant (all P < .05)
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, from January 2020 to January 2022, a total of 120 patients with early-stage type 2 diabetic nephropathy who met the inclusion criteria were selected. According to the order of treatment, the patients were randomly divided into traditional group, liraglutide group and dapagliflozin gro…
Report a problemFND-3829474417

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.